{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,31]],"date-time":"2025-08-31T17:10:15Z","timestamp":1756660215494,"version":"3.44.0"},"reference-count":34,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2022,9,30]],"date-time":"2022-09-30T00:00:00Z","timestamp":1664496000000},"content-version":"unspecified","delay-in-days":29,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"GSK","award":["Not applicable"],"award-info":[{"award-number":["Not applicable"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Resp Res"],"accepted":{"date-parts":[[2022,8,27]]},"published-print":{"date-parts":[[2022,9]]},"abstract":"<jats:p>The use of real-world evidence (RWE) studies, including pragmatic randomised controlled trials (RCTs; randomised RWE studies), to aid the development of treatment guidelines, is gradually becoming a mainstay within clinical practice. RWE is an integral part of patient-driven decision-making and offers important value to add complimentary evidence to traditional RCTs; these provide a more well-rounded view of the benefits to patient-reported outcomes and improve the external validity of a given treatment versus findings from traditional RCTs alone. Discussions in recent scientific workshops explored the importance of pragmatic RCTs in optimising guideline development and patient care in chronic obstructive pulmonary disease (COPD) and asthma. The Salford Lung Study in patients with COPD (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT01551758\">NCT01551758<\/jats:ext-link>) and asthma (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT01706198\">NCT01706198<\/jats:ext-link>) were the world\u2019s first prelicence pragmatic RCTs that compared novel investigational treatments with existing COPD and asthma treatments and, more recently (2021), RWE studies have been used by the American Thoracic Society and the US Food and Drug Administration to support the approval of an immunosuppressant drug in patients receiving lung transplants. This highlights the importance of RWE data in supporting clinical guideline development and emphasises the advantages for the use of pragmatic RCTs in guiding clinical practice.<\/jats:p>","DOI":"10.1136\/bmjresp-2022-001303","type":"journal-article","created":{"date-parts":[[2022,9,30]],"date-time":"2022-09-30T10:25:21Z","timestamp":1664533521000},"page":"e001303","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Pragmatic randomised controlled trials in COPD and asthma: how to guide clinical practice"],"prefix":"10.1136","volume":"9","clinical-trial-number":[{"clinical-trial-number":"nct01551758","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01706198","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01551758","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03467425","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01551758","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03467425","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01551758","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Nawar Diar","family":"Bakerly","sequence":"first","affiliation":[{"name":"School of Biological Sciences, Manchester Metropolitan University, Manchester, UK"},{"name":"Salford Royal, NHS Foundation Trust, Salford, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kirill","family":"Nikitin","sequence":"additional","affiliation":[{"name":"Respiratory Department, GSK, Brentford, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neil G","family":"Snowise","sequence":"additional","affiliation":[{"name":"Institute of Pharmaceutical Science, Faculty of Life Sciences and Medicine, King's College, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Glenn","family":"Cardwell","sequence":"additional","affiliation":[{"name":"Respiratory Department, GSK, Brentford, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daryl","family":"Freeman","sequence":"additional","affiliation":[{"name":"Norfolk Community Health and Care, Woodlands House, Norwich, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ravijyot","family":"Saggu","sequence":"additional","affiliation":[{"name":"Pharmacy Department, University College Hospital, NHS Foundation Trust, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony","family":"De Soyza","sequence":"additional","affiliation":[{"name":"Population and Health Sciences Institute, Newcastle University, Newcastle, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2022,9,30]]},"reference":[{"key":"2025083109442212000_9.1.e001303.1","doi-asserted-by":"crossref","first-page":"2885","DOI":"10.2147\/COPD.S118867","article-title":"Randomized controlled trials and real-world observational studies in evaluating cardiovascular safety of inhaled bronchodilator therapy in COPD","volume":"11","author":"Kardos","year":"2016","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2025083109442212000_9.1.e001303.2","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-018-1038-2"},{"key":"2025083109442212000_9.1.e001303.3","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.h2147"},{"key":"2025083109442212000_9.1.e001303.4","doi-asserted-by":"publisher","DOI":"10.1159\/000355082"},{"key":"2025083109442212000_9.1.e001303.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2004.03.026"},{"key":"2025083109442212000_9.1.e001303.6","first-page":"14","article-title":"Informing healthcare decisions with observational research assessing causal effect","volume":"203","author":"Gershon","year":"2020","journal-title":"American Thoracic Society Documents"},{"key":"2025083109442212000_9.1.e001303.7","first-page":"464","article-title":"Real-world evidence: promise and peril for medical product evaluation","volume":"43","author":"Dhruva","year":"2018","journal-title":"P T"},{"key":"2025083109442212000_9.1.e001303.8","unstructured":"US Food and Drug Administration. Real-world evidence, 2022. Available: https:\/\/www.fda.gov\/science-research\/science-and-research-special-topics\/real-world-evidence [Accessed 14 Jan 2022]."},{"key":"2025083109442212000_9.1.e001303.9","unstructured":"US Food and Drug Administration . FDA approval demonstrates the role of real-world evidence in regulatory decision-making on drug effectiveness, 2021. Available: https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approval-demonstrates-role-real-world-evidence-regulatory-decision-making-drug-effectiveness [Accessed 14 Jan 2022]."},{"key":"2025083109442212000_9.1.e001303.10","unstructured":"US Food and Drug Administration . FDA approves new use of transplant drug based on real-world evidence, 2021. Available: https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-new-use-transplant-drug-based-real-world-evidence [Accessed 14 Jan 2022]."},{"key":"2025083109442212000_9.1.e001303.11","unstructured":"US Food and Drug Administration . Framework for FDA\u2019s real world evidence program, 2018. Available: https:\/\/www.fda.gov\/media\/120060\/download [Accessed 14 Jan 2022]."},{"key":"2025083109442212000_9.1.e001303.12","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01718-2021","article-title":"Real-life evidence in ERS clinical practice guidelines: from foes to friends","volume":"58","author":"Fally","year":"2021","journal-title":"Eur Respir J"},{"key":"2025083109442212000_9.1.e001303.13","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jclinepi.2018.09.007","article-title":"Evidence to decision framework provides a structured \"roadmap\" for making GRADE guidelines recommendations","volume":"104","author":"Li","year":"2018","journal-title":"J Clin Epidemiol"},{"key":"2025083109442212000_9.1.e001303.14","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i2016"},{"key":"2025083109442212000_9.1.e001303.15","unstructured":"Schunemann H , Brozek J , Guyatt G . Introduction to grade Handbook. Handbook for grading the quality of evidence and the strength of recommendations using the grade approach, 2013."},{"key":"2025083109442212000_9.1.e001303.16","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1002\/cpt.2083","article-title":"Randomized controlled trials versus real world evidence: neither magic nor myth","volume":"109","author":"Eichler","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"2025083109442212000_9.1.e001303.17","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1056\/NEJMoa1608033","article-title":"Effectiveness of fluticasone furoate-vilanterol for COPD in clinical practice","volume":"375","author":"Vestbo","year":"2016","journal-title":"N Engl J Med"},{"key":"2025083109442212000_9.1.e001303.18","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1016\/S0140-6736(17)32397-8","article-title":"Effectiveness of fluticasone furoate plus vilanterol on asthma control in clinical practice: an open-label, parallel group, randomised controlled trial","volume":"390","author":"Woodcock","year":"2017","journal-title":"Lancet"},{"key":"2025083109442212000_9.1.e001303.19","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2014-205259"},{"key":"2025083109442212000_9.1.e001303.20","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00061-2019"},{"key":"2025083109442212000_9.1.e001303.21","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2021.106398","article-title":"TRICOP - A real-world effectiveness study with a single-inhaler extrafine triple therapy over 52 weeks in Austrian patients with COPD","volume":"182","author":"Marth","year":"2021","journal-title":"Respir Med"},{"key":"2025083109442212000_9.1.e001303.22","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.rmed.2019.09.008","article-title":"Real-Life inhaler adherence and technique: time to get smarter!","volume":"158","author":"Chrystyn","year":"2019","journal-title":"Respir Med"},{"key":"2025083109442212000_9.1.e001303.23","unstructured":"Medicines and Healthcare Products Regulatory Agency (MHRA) . Tiotropium delivered via Respimat compared with Handihaler: no significant difference in mortality in TIOSPIR trial, 2015. Available: https:\/\/www.gov.uk\/drug-safety-update\/tiotropium-delivered-via-respimat-compared-with-handihaler-no-significant-difference-in-mortality-in-tiospir-trial [Accessed 8 Dec 2022]."},{"key":"2025083109442212000_9.1.e001303.24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0113048"},{"key":"2025083109442212000_9.1.e001303.25","doi-asserted-by":"crossref","DOI":"10.1186\/s12931-021-01661-8","article-title":"Beta-blocker therapy in patients with COPD: a systematic literature review and meta-analysis with multiple treatment comparison","volume":"22","author":"Gulea","year":"2021","journal-title":"Respir Res"},{"key":"2025083109442212000_9.1.e001303.26","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00966-2020","article-title":"Safety data in randomised real-world evidence studies: Salford Lung Study learnings","volume":"7","author":"Harvey","year":"2021","journal-title":"ERJ Open Res"},{"key":"2025083109442212000_9.1.e001303.27","unstructured":"European Medicines Agency . Guideline on registry-based studies (draft version), 2020. Available: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-registry-based-studies_en.pdf [Accessed 12 Aug 2021]."},{"key":"2025083109442212000_9.1.e001303.28","unstructured":"Medicines and Healthcare Products Regulatory Agency (MHRA) . Consultation document: MHRA draft guidance on randomised controlled trials generating real-world evidence to support regulatory decision 2020. Available: https:\/\/www.gov.uk\/government\/consultations\/mhra-draft-guidance-on-randomised-controlled-trials-generating-real-world-evidence-to-support-regulatory-decisions\/consultation-document-mhra-draft-guidance-on-randomised-controlled-trials-generating-real-world-evidence-to-support-regulatory-decisions [Accessed 24 Jun 2021]."},{"key":"2025083109442212000_9.1.e001303.29","unstructured":"UK Department of Health and Social Care . Working together to improve health and social care for all 2021. Available: https:\/\/www.gov.uk\/government\/publications\/working-together-to-improve-health-and-social-care-for-all [Accessed 6 May 2021]."},{"key":"2025083109442212000_9.1.e001303.30","unstructured":"Global Initiative for Chronic Obstructive Lung Disease (GOLD) . Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease, 2021 report, 2021. Available: https:\/\/goldcopd.org\/wp-content\/uploads\/2020\/11\/GOLD-REPORT-2021-v1.1-25Nov20_WMV.pdf [Accessed 10 Aug 2021]."},{"key":"2025083109442212000_9.1.e001303.31","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00950-2020","article-title":"INTREPID: single- versus multiple-inhaler triple therapy for COPD in usual clinical practice","volume":"7","author":"Halpin","year":"2021","journal-title":"ERJ Open Res"},{"key":"2025083109442212000_9.1.e001303.32","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa063070"},{"key":"2025083109442212000_9.1.e001303.33","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/S0140-6736(16)30069-1","article-title":"Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial","volume":"387","author":"Vestbo","year":"2016","journal-title":"Lancet"},{"key":"2025083109442212000_9.1.e001303.34","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1516385"}],"container-title":["BMJ Open Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjresp-2022-001303","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,31]],"date-time":"2025-08-31T16:44:35Z","timestamp":1756658675000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopenrespres.bmj.com\/lookup\/doi\/10.1136\/bmjresp-2022-001303"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,9,30]]},"published-print":{"date-parts":[[2022,9]]}},"alternative-id":["10.1136\/bmjresp-2022-001303"],"URL":"https:\/\/doi.org\/10.1136\/bmjresp-2022-001303","relation":{},"ISSN":["2052-4439"],"issn-type":[{"type":"electronic","value":"2052-4439"}],"subject":[],"published":{"date-parts":[[2022,9]]}}}